Yasutomo Hori , 1 , Masayuki Iguchi 2 , Yasuhiro Heishima 1 , 3 , Yohei Yamashita 4 , Kensuke Nakamura 5 , Atsushi Hirakawa 6 , Akihito Kitade 7 , Toshiki Ibaragi 8 , Michio Katagi 9 , Tamotsu Sawada 10 , Masashi Yuki 11 , Nobuyuki Kanno 12 , Haruki Inaba 13 , Noriko Isayama 14 , Hideyuki Onodera 15 , Naoki Iwasa 16 , Mikio Kino 17 , Mikihiro Narukawa 18 , Syuhei Uchida 19
16 April 2018
Cardiac troponin I (cTnI) is useful for assessing hypertrophic cardiomyopathy (HCM) in cats.
To measure plasma cTnI concentrations in healthy cats and evaluate the clinical utility of cTnI in determining the severity of HCM.
Multicenter prospective study. Cats with HCM, including hypertrophic obstructive cardiomyopathy at various stages, were diagnosed using echocardiography. Plasma cTnI concentrations were analyzed by a commercial laboratory. Receiver‐operating characteristic curve analysis was used to evaluate the accuracy of plasma cTnI concentrations to detect HCM.
The median cTnI concentration was 0.027 ng/mL (interquartile range, 0.012‐0.048 ng/mL) in healthy cats. Concentrations were significantly higher in diseased cats than in healthy controls, and concentrations were significantly higher in cats with heart failure than in asymptomatic cats. A plasma cTnI concentration of 0.163 ng/mL had a sensitivity of 62.0% and specificity of 100% when used to distinguish normal cats from asymptomatic HCM cats without left atrial dilatation. A cutoff of 0.234 ng/mL had high sensitivity (95.0%) and specificity (77.8%) for assessing heart failure. The areas under the receiver‐operating characteristic curves were 0.85 and 0.93, respectively.